LOGIN  |  REGISTER

Latest Collaborations and Licensing Agreement News

Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line

January 17
Last Trade: 1.06 0.00 0.00

RA'ANANA, ISRAEL, Jan. 17, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced that the Company is establishing a dedicated production line for a crucial component of its innovative respiratory support system, in collaboration with Zriha Medical Ltd ("Zriha Medical"), a leading international manufacturer specializing in...Read more


Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

January 16
Last Trade: 36.66 -0.65 -1.74

Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal DNA methylation measurements and comprehensive genomic profiling allow deeper insights into intrinsic and acquired resistance mechanisms PALO ALTO, Calif., & CAMBRIDGE, Mass. / Jan 16, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,...Read more


Charles River Laboratories and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

January 16
Last Trade: 163.50 -2.30 -1.39

WILMINGTON, Mass. / Jan 16, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron’s Closed System Solutions (CSS)™ line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River’s Cell Therapy Flex Platform for Process Development....Read more


Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

January 15
Last Trade: 9.09 0.16 1.79

Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance First program member is Segal Trials, a preferred provider for leading pharmaceutical companies globally Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in...Read more


University of California San Francisco and GE HealthCare Launch a Joint Research Program to Drive Innovations in Imaging, Brain Health and Precision Oncology

January 15
Last Trade: 84.74 -0.26 -0.31

New joint research program combines UCSF’s advanced clinical and research teams with GE HealthCare’s technical and engineering expertise to develop solutions that directly impact patient care. The collaboration aims to address two of the most prevalent disease states worldwide, neurodegenerative disease and cancer, by increasing accessibility of imaging, driving clinical impact and translating techniques to diagnose and treat these...Read more


Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

January 15
Last Trade: 2.15 0.17 8.59

Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products Second project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) --  Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and...Read more


Sutter Health and GE HealthCare enter strategic partnership to benefit patients, physicians and clinicians with advanced, AI-powered imaging

January 14
Last Trade: 84.74 -0.26 -0.31

The multi-year collaboration enables expanded access to quality diagnostic care for patients in California and provides Sutter physicians and clinicians with access to technology advances and innovations. It will also drive ongoing, comprehensive training and education, fostering future healthcare professionals representing the diverse communities they serve. Sutter Health, one of the top integrated health delivery systems in the country...Read more


DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets

January 14
Last Trade: 0.69 0.04 6.74

New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK, Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a...Read more


Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

January 14
Last Trade: 6.81 -0.11 -1.59

SEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (Nasdaq:NEO), a leading oncology testing services company, today announced a multi-year exclusive strategic commercial collaboration that will...Read more


Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

January 14
Last Trade: 12.87 0.30 2.39

STAFFORD, Texas, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of clinical sites in Germany. The Company has partnered with GBG (German Breast Group), the largest academic breast...Read more


IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions

January 13
Last Trade: 197.36 -0.30 -0.15

RESEARCH TRIANGLE PARK, N.C. / Jan 13, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences. The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered...Read more


Illumina and NVIDIA collaborate to decode biology and propel precision health

January 13
Last Trade: 136.67 -0.70 -0.51

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in...Read more


AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

January 13
Last Trade: 2.97 -0.06 -1.98

VANCOUVER, British Columbia / Jan 13, 2025 / Business Wire / AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for tumor targets. “We are pleased...Read more


AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

January 13
Last Trade: 171.56 -7.64 -4.26

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized...Read more


Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI

January 13
Last Trade: 0.19 -0.02 -9.52

VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful achievement of a shortlist of AI-generated molecules targeting ATR (Ataxia Telangiectasia and Rad3-related protein) with specific designs for central nervous system (CNS)...Read more


Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

January 13
Last Trade: 118.39 -1.14 -0.95

WALTHAM, Mass. & SAN DIEGO / Jan 13, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated...Read more


Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

January 13
Last Trade: 10.83 0.63 6.18

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON, Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation...Read more


Progyny: Cigna Healthcare Expands Access to Fertility and Family-Building Benefits and Services

January 13
Last Trade: 21.00 0.38 1.84

BLOOMFIELD, Conn., Jan. 13, 2025 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today announced a new offering in collaboration with Progyny, Inc (Nasdaq: PGNY) that makes best-in-class fertility and family-building services accessible and equitable for more employers. This new and comprehensive benefit will enable employers to offer expanded coverage throughout the entire fertility journey,...Read more


X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

January 13
Last Trade: 0.51 0.05 10.15

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties Upfront non-dilutive funds strengthen X4’s balance sheet as enrollment ramps up in the company’s global Phase 3 clinical trial in chronic neutropenia Agreement underscores Norgine’s commitment to bring transformative therapies to patients in...Read more


Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France 

January 13
Last Trade: 12.87 0.30 2.39

STAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the activation of clinical sites in France. According to the latest data collected by the European Cancer Information System (click...Read more


Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

January 13
Last Trade: 33.37 0.59 1.80

BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic...Read more


Regeneron Pharmaceuticals Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

January 13
Last Trade: 681.58 -11.65 -1.68

The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project Extensively expanded database effort is designed to dramatically accelerate...Read more


Teva Pharmaceutical Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

January 13
Last Trade: 21.92 0.24 1.11

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis®2 (ranibizumab) in Europe The partnership broadens Teva's biosimilars portfolio, in line with its Pivot to Growth strategy TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE)...Read more


Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

January 12
Last Trade: 39.45 -0.20 -0.50

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ leading Biclonics® technology platform, and Biohaven’s next-generation ADC conjugation and payload platform...Read more


Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

January 12
Last Trade: 5.56 -0.25 -4.30

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to ten Expanded partnership highlights the parties’ emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med’s expertise in the development of 212Pb-based TAT and vast proprietary supply of 212Pb and Molecular Partners’ unique Radio-DARPins as an ideal vector for...Read more


Gilead Sciences and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

January 11
Last Trade: 91.84 0.19 0.21

Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in...Read more


Samsung Bioepis and Teva Pharmaceutical Enter into Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

January 10
Last Trade: 21.92 0.24 1.11

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U.S. Partnership supports Teva's Pivot to Growth strategy and adds to its broad biosimilar portfolio INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries...Read more


Vertex Pharmaceuticals and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

January 10
Last Trade: 422.00 5.04 1.21

Exclusive collaboration and licensing agreement for povetacicept in the region Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved BOSTON & SHANGHAI & CAMBRIDGE, Mass. / Jan 10, 2025 / Business Wire / Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688)...Read more


Zai Lab and Vertex Pharmaceuticals Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

January 10
Last Trade: 26.05 0.67 2.64

Exclusive collaboration and licensing agreement for povetacicept in the region Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved SHANGHAI & CAMBRIDGE, Mass. & BOSTON / Jan 10, 2025 / Business Wire / Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)...Read more


Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

January 10
Last Trade: 2.90 0.13 4.69

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the...Read more


PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

January 10
Last Trade: 1.64 0.04 2.50

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered...Read more


Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

January 9
Last Trade: 26.05 0.67 2.64

SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass. / Jan 09, 2025 / Business Wire / Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Through this...Read more


Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

January 9
Last Trade: 35.15 0.40 1.15

CHICAGO / Jan 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient...Read more


Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

January 9
Last Trade: 3.01 0.00 0.00

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs Preclinical Data Expected to be Shared Later in 2025 WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced it has entered into an exclusive license...Read more


Tempus AI Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

January 8
Last Trade: 35.15 0.40 1.15

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers...Read more


Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

January 8
Last Trade: 7.75 0.00 0.00

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People’s Republic of...Read more


Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

January 8
Last Trade: 78.77 -4.30 -5.18

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular disease Expanded collaboration includes near-term payments totalling up to 190 million US dollars, while Valo is eligible to receive milestone payments of approximately 4.6 billion dollars, plus R&D funding and potential royalty...Read more


Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

January 8
Last Trade: 2.90 0.13 4.69

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. AMD will also make a $20 million investment in Absci, structured as a private investment in...Read more


Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

January 7
Last Trade: 35.15 -2.38 -6.34

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems. The research collaboration will rely on the UVA Center for Diabetes...Read more


MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

January 7
Last Trade: 2.00 -0.02 -0.94

Phase 2 pivotal trials to evaluate efficacy of THIO in combination with BeiGene’s checkpoint inhibitor (CPI) tislelizumab CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply agreement with global oncology company BeiGene to assess the...Read more


Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

January 7
Last Trade: 2.01 0.16 8.65

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta), Sutro’s Tubulin FRα-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer and other FRα...Read more


Hummingbird Bioscience Licenses Novel Antibodies to Immunome

January 7
Last Trade: 9.99 0.13 1.32

SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are...Read more


MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

January 7
Last Trade: 12.39 -0.13 -1.04

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research...Read more


Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

January 7
Last Trade: 422.00 5.04 1.21

Collaboration to leverage Orna's differentiated lipid nanoparticle (LNP) delivery solutions for patients with SCD and TDT  Orna to receive an upfront payment and is eligible to receive potential pre-clinical, clinical, and commercialization milestone payments and royalties  WATERTOWN, Mass., Jan. 7, 2025 /PRNewswire/ -- Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a...Read more


iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

January 7
Last Trade: 2.81 -0.04 -1.23

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio’s patented Machine-Learning Antibody Engine. Developing an antibody against Activin E, a...Read more


GeneTether Therapeutics Announces Closing of Licensing Agreement for STS-201 and $500,000 Non-Brokered Private Placement

January 6
Last Trade: 0.10 0.00 0.00

Kelowna, British Columbia – January 6, 2025 – TheNewswire - GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “GeneTether” or the “Company”) (CSE: GTTX) is pleased to announce the successful closing of its two previously announced transactions: Licensing Agreement for STS-201  The Company has successfully closed the previously announced licensing agreement for STS-201 (the “License”), a...Read more


IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

December 29
Last Trade: 22.18 -0.54 -2.38

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC) DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), respectively 85% and 20-40% Rational combination opportunities with IDEAYA's DNA Damage Repair (DDR) clinical pipeline, including Phase 1 PARG inhibitor IDE161 Targeting US IND filing for SHR-4849 in H1...Read more


Exicure Partners with GPCR Therapeutics to Fuel New Growth in Biotech

December 26
Last Trade: 10.07 1.18 13.27

CHICAGO / Dec 26, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (“GPCR Therapeutics”) on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics’ ongoing drug development pipelines. Through this...Read more


Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

December 26
Last Trade: 1.50 -0.08 -5.06

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001 NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S....Read more


Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

December 23
Last Trade: 0.80 -0.03 -3.08

WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently...Read more


RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

December 23
Last Trade: 1.20 0.01 0.84

RAPT obtains worldwide rights excluding China  Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales  Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China  RAPT plans to initiate Phase 2b trial in food allergy next year  RAPT to host a conference call at 8:30...Read more


Voyageur Pharmaceuticals Signs Letter of Intent with Global Contrast Imaging Company to Expand Market Reach and Product Portfolio

December 20
Last Trade: 0.14 -0.005 -3.57

LOI Agreement is steppingstone to formal agreement,  The Multinational Pharmaceutical company is ranked in the top five contrast agent suppliers in the world, signaling and solidifying Voyageur’s importance in the global contrast agent market  Calgary, Alberta, Canada – TheNewswire - December 20, 2024 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") a vertically integrated...Read more


Renovaro Enters into Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

December 20
Last Trade: 0.71 -0.04 -5.73

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic...Read more


Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

December 20
Last Trade: 97.92 -2.78 -2.76

RAHWAY, N.J. / Dec 20, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. As previously announced, Merck will develop, manufacture and commercialize LM-299. Merck will record a pre-tax charge relating to the upfront payment of $588...Read more


Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

December 20
Last Trade: 45.74 -1.25 -2.66

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential...Read more


Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

December 19
Last Trade: 2.98 -0.02 -0.67

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC   Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former...Read more


Modular Medical Announces Licensing and Partnership Agreement With Nudge BG

December 19
Last Trade: 1.21 -0.01 -0.82

Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first...Read more


Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

December 19
Last Trade: 4.89 0.11 2.30

FREMONT, Calif. / Dec 19, 2024 / Business Wire / Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and...Read more


Prenetics Global IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

December 19
Last Trade: 5.66 0.23 4.24

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics’ (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to...Read more


Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

December 19
Last Trade: 0.84 -0.004 -0.47

Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC...Read more


Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

December 19
Last Trade: 2.98 0.08 2.76

BOSTON / Dec 19, 2024 / Business Wire / Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling. In the field of...Read more


Astellas Pharma and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

December 19
Last Trade: 1.09 -0.01 -0.91

 - Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales - TOKYO and RICHMOND, Calif.,...Read more


Sangamo Therapeutics and Astellas Pharma Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

December 19
Last Trade: 1.09 -0.01 -0.91

Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales RICHMOND, Calif. & TOKYO / Dec 19, 2024 /...Read more


Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

December 18
Last Trade: 97.92 -2.78 -2.76

RAHWAY, N.J. / Dec 18, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. “We continue to leverage science-driven business development to augment and complement our robust...Read more


BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

December 18
Last Trade: 5.14 0.10 1.98

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) --...Read more


Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

December 18
Last Trade: 36.66 -0.65 -1.74

PALO ALTO, Calif. / Dec 18, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal...Read more


DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

December 18
Last Trade: 4.17 -0.10 -2.34

NEW YORK / Dec 18, 2024 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. This expanded collaboration, initially launched in the New York-New Jersey area, will now bring advanced...Read more


Gilead Sciences and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

December 17
Last Trade: 91.84 0.19 0.21

Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest  Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration  FOSTER CITY, Calif. & LOS ANGELES / Dec 17, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a...Read more


EUDA Health and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation

December 16
Last Trade: 3.60 -0.20 -5.26

Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”), a...Read more


Clearmind Medicine and Dr Glitter Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

December 16
Last Trade: 1.49 -0.03 -1.97

The term sheet is non-binding, subject to the execution of a definitive agreement  Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has signed a non-binding term...Read more


Personalis and Tempus Expand Collaboration to Biopharma

December 16
Last Trade: 4.89 0.11 2.30

Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution FREMONT, Calif. / Dec 16, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of...Read more


Forian Partners With Databricks to Expand Access to Advanced Healthcare Analytics

December 16
Last Trade: 2.03 -0.06 -3.01

NEWTOWN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced a partnership with Databricks, the data and AI company, to deliver access to its Chartis™ product, which maps physician and organization affiliations, through Databricks Marketplace. This collaboration...Read more


Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

December 16
Last Trade: 18.58 0.13 0.70

BURLINGAME, Calif. / Dec 16, 2024 / Business Wire / Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), for the commercialization of Zevtera® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the United States. "The licensing of Zevtera expands...Read more


BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

December 12
Last Trade: 184.71 0.00 0.00

SAN MATEO, Calif. / Dec 12, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid...Read more


Spectral AI Highlights Unprecedented Collaboration with National Leaders in Burn Care for DeepView™ System Training and Validation Studies

December 12
Last Trade: 1.96 -0.12 -5.77

DALLAS, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced that national leaders in burn care have dedicated more than an estimated 511 in-person days of physician engagement to...Read more


Bio-Techne Announces New Distribution Agreement With Medsantek To Expand Access To Portfolio Across Turkey

December 12
Last Trade: 75.83 -0.27 -0.35

MINNEAPOLIS, Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen brands across...Read more


CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

December 11
Last Trade: 21.44 -0.62 -2.81

CareDx Continues Strategic Expansion into Hematology Oncology with Pharmacokinetic and Monitoring Assays for Cell Therapy Patients BRISBANE, Calif. / Dec 11, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –...Read more


TC Biopharm Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

December 11
Last Trade: 0.38 -0.01 -3.61

EDINBURGH, Scotland, Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE...Read more


PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

December 11
Last Trade: 3.30 0.11 3.45

PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. (“ImmunoGenesis”), a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development of novel...Read more


Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

December 11
Last Trade: 5.66 -0.10 -1.74

BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the closing of the Company’s previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs, including MRT-6160. Under the terms of the agreement, Novartis will...Read more


Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

December 10
Last Trade: 2.82 0.06 2.17

MARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma, today announced an exclusive global license agreement to develop and commercialize NeraCare’s Immunoprint test on Akoya's multiplexed immunofluorescent platform. Building on the research collaboration between...Read more


NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes...

December 10
Last Trade: 0.45 -0.02 -4.31

Collaboration leverages NeuroBiogen’s research and development of novel oral tablet KDS2010 and Scilex’s commercial and development expertise in central nervous system (CNS) and primary care diseases. Novel oral tablet KDS2010, a recently synthesized potent, selective, and reversible MAO-B inhibitor will be the collaboration’s lead product candidate, targeting the fast growing $150 billion weight loss and Alzheimer’s disease...Read more


NetraMark Signs A Pilot Collaboration Agreement With A Top 5 Pharmaceutical Company

December 9
Last Trade: 0.94 0.09 10.59

TORONTO, Dec. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is proud to announce that it has entered into a pilot collaboration agreement with a Top 5 pharmaceutical company. The pilot is seeking to unlock novel insights and hypotheses regarding...Read more


OmniScience and INmune Bio Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

December 4
Last Trade: 6.45 -0.27 -4.02

Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease (AD) clinical trial (the “AD02 trial”) using OmniScience’s flagship...Read more


Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

December 4
Last Trade: 7.77 0.77 11.00

$10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts  SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the initiation of a strategic partnership with a...Read more


Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies

December 4
Last Trade: 3.27 0.02 0.62

Solid Biosciences to collaborate with Mayo Clinic’s genetic cardiology disease laboratory  Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy platform and multiple next-generation cardiac gene therapy programs developed by Mayo Clinic’s Windland Smith Rice Sudden Death Genomics Lab  CHARLESTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the...Read more


Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

December 4
Last Trade: 1.72 -0.01 -0.58

Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a pharmaceutical company focused on the development and commercialization of innovative therapies, today announced it has entered into an agreement...Read more


Inspira Technologies Collaborates with New York's Westchester Medical Center to Evaluate the INSPIRA™ ART100 Functionality and Performance in Clinical Scenarios

December 4
Last Trade: 1.06 0.00 0.00

RA'ANANA, Israel, Dec. 4, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN), (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, entered into a strategic collaboration with Westchester Medical Center in Valhalla, New York. Westchester Medical Center, the flagship hospital in the Westchester Medical Center Health Network, will evaluate the...Read more


Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

December 3
Last Trade: 3.71 -0.01 -0.27

BASKING RIDGE, N.J. and HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Kuva Labs, a wholly owned subsidiary of Mi2 Holdings, LLC (“Kuva”), are pleased to announce a global collaboration and license agreement. Under the terms of this agreement...Read more


Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

December 3
Last Trade: 4.46 0.14 3.24

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE